



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Holaday et al.

Serial No. 10/799,163

Filed: March 12, 2004

For: Methods and Compositions for Treating  
Cancer and Hyperproliferative Disorders

)  
)  
) Art Unit: 1653  
)  
)  
)  
)  
)

INFORMATION DISCLOSURE STATEMENT

Mail Stop - Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The citation of information on the attached Form PTO/SB/08 is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed with the exception that copies of U.S. patents are not being provided pursuant to the waiver of 37 C.F.R. for patent applications filed after June 30, 2003.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Kilpatrick Stockton LLP  
1100 Peachtree Street, Ste. 2800  
Atlanta, Georgia 30309-4530  
(404) 815-6500  
Our Docket: 05213-0077 (43170-296614)


Respectfully submitted,

*Sima Singadia Kulkarni*  
Sima Singadia Kulkarni  
Reg. No. 43,732

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 13<sup>th</sup> day of August, 2004.

*Sima Singadia Kulkarni*  
Sima Singadia Kulkarni - Reg. No. 43,732

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO				Complete if Known		
				Application No.	10/799,163	
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Filing Date	03/12/2004	
				First Named Inventor	John W. Holaday	
				Group Art Unit	1653	
				Examiner Name	Unassigned	
Sheet <input type="text"/> of <input type="text"/> 4				Attorney Docket Number	05213-0077 (43170-296614)	
<b>U.S. PATENT DOCUMENTS</b>						
Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number <sup>2</sup>	Kind Code <sup>3</sup> (if known)			
	1	5,252,718	A	Baird et al.	10/12/1993	
	2	5,288,704	A	Ungheri et al.	02/22/1994	
	3	5,629,327		D'Amato	05/13/1997	
	4	5,639,725		O'Reilly et al.	06/17/1997	
	5	5,733,876		O'Reilly et al.	03/31/1998	
	6	5,792,845		O'Reilly et al.	08/11/1998	
	7	5,854,205		O'Reilly et al.	12/29/1998	
	8	5,919,459	A	Nacy et al.	07/06/1999	
	9	6,346,510	B1	O'Reilly et al.	02/12/2002	
	10	6,413,513	B1	Holaday, John	07/02/2002	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)					Complete if Known			
					Application No.	10/799,163		
					Filing Date	03/12/2004		
					First Named Inventor	John W. Holaday		
					Group Art Unit	1653		
					Examiner Name	Unassigned		
Sheet	2	of	4	Attorney Docket Number	05213-0077 (43170-296614)			
<b>FOREIGN PATENT DOCUMENTS</b>								
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document		Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>					
	11	EP	0281822	A2	Takeda Chemical Industries, Ltd.	09/14/1988		
	12	EP	0657175	A2	Centro de Immunologia Molecular	06/14/1995		
	13	Japa	09316000	A	Toagosei Co. Ltd.	09/12/1997		
	14	WO	94/21288	A1	Assay Research, Inc.	09/29/1994		
	15	WO	94/27635	A	EntreMed, Inc.	12/08/1994		
	16	WO	99/45018	A1	Imclone Systems Incorporated	09/10/1999		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document, by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number



Substitute for Form 1449/A/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 4

## Complete if Known

Application No.	10/799,163
Filing Date	03/12/2004
First Named Inventor	John W. Holaday
Group Art. Unit	1653
Examiner Name	Unassigned
Attorney Docket Number	05213-0077 (43170-296614)

## **OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	17	<p>Author: BAIRD et al. Title: Receptor- and Heparin-Binding Domains of Basic Fibroblast Growth Factor</p> <p>Publ: Proceedings of the National Academy of Sciences</p> <p>Vol/Iss: 85 Pages: 2324-2328 Date: 04/1988</p>	
	18	<p>Author: BALIAN et al. Title: Structure of Rat Skin Collagen <math>\alpha 1</math>-CB8. Amino Acid Sequence of the Hydroxylamine-Produced Fragment HA2</p> <p>Publ: Biochemistry</p> <p>Vol/Iss: 11 (20) Pages: Date:</p>	
	19	<p>Author: ENJOJOI, K. et al. Title: Effect of Heparin on the Inhibition of Factor Xa by Tissue Factor Pathway Inhibitor: A Segment, Gly<sup>112</sup>-Phe<sup>160</sup>, of the third Kunitz Domain is a Heparin-Binding Site</p> <p>Publ: Biochemistry</p> <p>Vol/Iss: 34 (17) Pages: 5725-5735 Date: 1995</p>	
	20	<p>Author: FOLKMAN, J. Title: Tumor Angiogenesis: Therapeutic Implications</p> <p>Publ: New England Journal of Medicine</p> <p>Vol/Iss: 285 (21) Pages: 1182-1186 Date: 11/18/71</p>	
	21	<p>Author: PLUM et al. Title: Vaccination with Peptide to the Heparin Binding Domain of bFGF Conjugated to Liposomes Inhibits bFGF Induced Neovascularization (Abstract only)</p> <p>Publ: Proceedings of the American Association for Cancer Research Annual</p> <p>Vol/Iss: 39 Pages: 8 Date: 03/1998</p>	
	22	<p>Author: PLUM et al. Title: Administration of a Liposomal FGF-2 Peptide Vaccine Leads to Abrogation of FGF-2-Mediated Angiogenesis and Tumor Development</p> <p>Publ: Vaccine</p> <p>Vol/Iss: 19 (9-10) Pages: 1294-1303 Date: 2000</p>	
	23	<p>Author: SEAVER, Sally Title: Monoclonal Antibodies in Industry: More Difficult than Originally Thought</p> <p>Publ: Genetic Engineering News</p> <p>Vol/Iss: 14 Pages: 10 and 21 Date: 08/1994</p>	

Examiner Signature	Date Considered
--------------------	-----------------

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application No.	10799,163
				Filing Date	03/12/2004
				First Named Inventor	John W. Holaday
				Group Art. Unit	1653
				Examiner Name	Unassigned
Sheet	4	of	4	Attorney Docket Number	05213-0077 (43170-296614)
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T*
	24	Author: SOKER et al. Title: Neuregulin-1 is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor  Publ: Cell  Vol/Iss: 92 Pages: 735-745 Date: 03/20/1998			
	25	Author: TALARICO et al. Title: Protection of Mice Against Tumor Growth by Immunization with an Oncogene-Encoded Growth Factor  Publ: Proceedings of the National Academy of Science USA  Vol/Iss: 87 Pages: 4222-4225 Date: 06/1990			
	26	Author: VERMA, ALVING et al. Title: Adjuvant Effects of Liposomes Containing Lipid A: Enhancement of Liposomal Antigen Presentation and Recruitment of Macrophages (Abstract only)  Publ: Infect. Immun.  Vol/Iss: 60 (6) Pages: 2438-2444 Date: 1992			
	27	Author: WEBB et al. Title: Cell-Surface Expression and Purification of Human CD-4 Produced in Baculovirus-Infected Insect Cells (Abstract only)  Publ: Proceedings of the National Academy of Science (USA)  Vol/Iss: 86 (20) Pages: 7731-7735 Date: 1989			

Examiner Signature	Date Considered
--------------------	-----------------

\*Unique citation designation number. \*See attached Kinds of U.S. Patent Documents. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \*Applicant is to place a check mark here if English language translation is attached.